Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 12, 2008. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than general financial performance.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary Share ADRs. On February 8, 2008, an increase in the notional allocation of Ordinary Share ADRs occurred at a price of $42.16 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: The notional allocation increase occurred on February 8, 2008.
- Transaction Price: $42.16 per ADR.
- Involved Parties: The transaction involved Dr. J P Garnier (130 shares), Dr. M Slaoui (13 shares), Dr. R G Greig (34 shares), Mr. W C Louv (7 shares), Dr. D Pulman (9 shares), Mr. D M Stout (62 shares), and Mr. C Viehbacher (14 shares).
- Plan Context: The shares are part of the US Retirement Savings Plan and are notionally held in GSK Ordinary Share ADRs.